Skip to main content
. 2015 Sep 14;6:8266. doi: 10.1038/ncomms9266

Figure 8. GITR ligation induces Th9-mediated anti-tumour immunity in vivo.

Figure 8

(a) Rag1−/− mice were injected with B16-OVA melanoma cells together with sorted CD4+ T cells from OT-II mice. The host mice were treated with 3 doses of DTA-1 (0.5 mg, i.p., n=14) or control IgG (n=14) every five days starting from Day 5 after B16 inoculation. A cohort of anti-GITR treated Rag-1−/− mice (n=7) was also given a neutralizing anti-IL-9 mAb (0.2 mg, i.p.). All animals were sacrificed on day 18 for analysis. (b) Numbers of tumor foci in the lungs from mice treated as in (a) (left panel). Representative images of the lungs of mice receiving different treatments (right panel). (c) Quantitative RT–PCR analysis of Foxp3, Il9, Il17a, IFNγ and Il4 mRNA from the lung infiltrating CD4+ cells. Data represent mean values±s.d. (n=6). (d) Percentage of Foxp3+ (left) or IL-9+ (right) cells among the lung infiltrating CD4+ cells and in host spleen from control IgG and DTA treated mice as assessed by flow cytometry. Data represent mean values±s.d. (n=6). P-values were determined by Student's t-test (*P<0.05).